3rd Quarter - Report — DIALYSIS PATIENT CITIZENS for DIALYSIS PATIENT CITIZENS (2012)

Firm

DIALYSIS PATIENT CITIZENS

Client

DIALYSIS PATIENT CITIZENS

Income

—

Expenses

$20,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Coverage of End Stage Renal Disease (ESRD) in Essential Health Benefits Application of premium tax credits and cost-sharing subsidies for ESRD patients in health exchanges Ensuring adequacy of networks and consumer protections for ESRD patients in the exchanges S. 2163 / H.R. 6011 - To promote equitable access, prevention and research for kidney disease patients

Lobbyist	Covered position, as disclosed
HRANT JAMGOCHIAN	—
CARRIE E LAMB	—

Contacted: Veterans Affairs, Dept of (VA); Treasury, Dept of; HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); White House Office

Bills named: S. 2163 (112th), H.R. 6011 (112th)

Medicare/Medicaid MMM

S.1454 / H.R. 2969 - Extend Medicare coverage of immunosuppressive medications for kidney transplant patients S. 3271 - Extend guaranteed issue of Medigap policies for kidney disease patients Potential incentives for innovation inn ESRD bundled payment system Transition of oral-only medications into ESRD bundle

Lobbyist	Covered position, as disclosed
HRANT JAMGOCHIAN	—
CARRIE E LAMB	—

Contacted: Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); Treasury, Dept of; HOUSE OF REPRESENTATIVES; White House Office; SENATE; Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); Food & Drug Administration (FDA)

Bills named: S. 1454 (112th), H.R. 2969 (112th), S. 3271 (112th)

Budget/Appropriations BUD

Urge Congress to avoid sequestration and the disproportionate cuts for treating ESRD patients Facilitating patient choice and access to all modalities for VA dialysis patients H.R. 6482 - to better reflect the impact of prevention in scoring potential legislation Address reimbursement cuts restricting access to intradialytic parenteral therapy (IDPN) & intraperitoneal parenteral nutrition (IPN)

Lobbyist	Covered position, as disclosed
HRANT JAMGOCHIAN	—
CARRIE E LAMB	—

Contacted: Treasury, Dept of; Health Resources & Services Administration (HRSA); White House Office; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE; Internal Revenue Service (IRS); Veterans Affairs, Dept of (VA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 6482 (112th)

Medical/Disease Research/Clinical Labs MED

Supporting innovative pilots to reduce and potentially prevent ESRD, as well as improve their quality of life Importance of anemia management for ESRD patients Prioritizing role of patients in the Quality Incentive Process Prioritize patient safety in developing procedure for approval of "generic" IV Iron

Lobbyist	Covered position, as disclosed
HRANT JAMGOCHIAN	—

Contacted: White House Office; Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); Treasury, Dept of; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Internal Revenue Service (IRS); SENATE; Veterans Affairs, Dept of (VA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.